

## Special Issue

# Combination Therapy in Geriatric Population with Cancer

### Message from the Guest Editor

The increasing life expectancy of the population will, therefore, result in an increasing number of older patients with cancer. Treatment decisions in the older population are often challenging. Firstly, the older population is more vulnerable in terms of frailty, organ reserve, co-morbidities, polypharmacy and expectations. Secondly, registration trials predominantly include young and fit patients due to the stringent in, resulting in a lack of data about those outside of these requirements. In addition, the main endpoints of these trials are often survival-related. Consequently, there is a lack of knowledge on the efficacy, safety, pharmacodynamics and pharmacokinetics of treatments in older patients. In this Special Issue of *Cancers*, we welcome original research articles or comprehensive review articles focusing on different treatments (including surgery, radio-, chemo-, immunotherapy, targeted therapy and combinations) for older patients with cancer, regardless of cancer type.

---

### Guest Editor

Prof. Dr. Lore Decoster

Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium

---

### Deadline for manuscript submissions

closed (30 November 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/154825](https://mdpi.com/si/154825)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)